Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial

Leslie Baumann, David J. Goldberg, Linda Stein Gold, Emil A. Tanghetti, Edward Lain, Joely Kaufman, Emily Weng, David R. Berk, Gurpreet Ahluwalia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rosacea is a chronic dermatologic condition with limited treatment options, particularly for persistent erythema. This pivotal phase 3 study evaluated oxymetazoline, an a1A-adrenoceptor agonist, for the treatment of moderate to severe persistent erythema of rosacea. Eligible patients were randomly assigned 1:1 to receive oxymetazoline cream 1.0% or vehicle applied topically to the face once daily for 29 days. The primary efficacy outcome was ≥2-grade improvement from baseline on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success) at 3, 6, 9, and 12 hours postdose on day 29. Digital image analysis of rosacea facial erythema was evaluated as a secondary efficacy outcome measure. Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability. Patients were followed for 28 days posttreatment to assess worsening of erythema (1-grade increase in severity from baseline on composite CEA/SSA in patients with moderate erythema at baseline; rebound effect). The study included 445 patients (mean age: 50.3 years; 78.7% female); most had moderate erythema at baseline (84.0% on CEA; 91.5% on SSA). The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P=0.011, respectively). Median reduction in rosacea facial erythema on day 29 as assessed by digital image analysis also favored oxymetazoline over vehicle (P less than 0.001). Safety results were similar between oxymetazoline and vehicle; discontinuations due to TEAEs were low (2.7% vs 0.5%). Following cessation of treatment, 2 (1.2%) patients in the oxymetazoline group and no patient in the vehicle group had rebound effect compared with their day 1 baseline score. Topical oxymetazoline applied to the face once daily for 29 days was effective, safe, and well tolerated in the treatment of moderate to severe persistent facial erythema of rosacea.

J Drugs Dermatol. 2018;17(3):290-298.

.
Original languageEnglish (US)
Pages (from-to)290-298
Number of pages9
JournalJournal of drugs in dermatology : JDD
Volume17
Issue number3
StatePublished - Mar 1 2018

Fingerprint

Oxymetazoline
Rosacea
Erythema
Safety
Therapeutics
Withholding Treatment
Adrenergic Receptors

ASJC Scopus subject areas

  • Dermatology

Cite this

Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea : Findings from the Second REVEAL Trial. / Baumann, Leslie; Goldberg, David J.; Stein Gold, Linda; Tanghetti, Emil A.; Lain, Edward; Kaufman, Joely; Weng, Emily; Berk, David R.; Ahluwalia, Gurpreet.

In: Journal of drugs in dermatology : JDD, Vol. 17, No. 3, 01.03.2018, p. 290-298.

Research output: Contribution to journalArticle

Baumann, L, Goldberg, DJ, Stein Gold, L, Tanghetti, EA, Lain, E, Kaufman, J, Weng, E, Berk, DR & Ahluwalia, G 2018, 'Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial', Journal of drugs in dermatology : JDD, vol. 17, no. 3, pp. 290-298.
Baumann, Leslie ; Goldberg, David J. ; Stein Gold, Linda ; Tanghetti, Emil A. ; Lain, Edward ; Kaufman, Joely ; Weng, Emily ; Berk, David R. ; Ahluwalia, Gurpreet. / Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea : Findings from the Second REVEAL Trial. In: Journal of drugs in dermatology : JDD. 2018 ; Vol. 17, No. 3. pp. 290-298.
@article{b56af2cc12234774bd08496ef4b69012,
title = "Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0{\%} for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial",
abstract = "Rosacea is a chronic dermatologic condition with limited treatment options, particularly for persistent erythema. This pivotal phase 3 study evaluated oxymetazoline, an a1A-adrenoceptor agonist, for the treatment of moderate to severe persistent erythema of rosacea. Eligible patients were randomly assigned 1:1 to receive oxymetazoline cream 1.0{\%} or vehicle applied topically to the face once daily for 29 days. The primary efficacy outcome was ≥2-grade improvement from baseline on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success) at 3, 6, 9, and 12 hours postdose on day 29. Digital image analysis of rosacea facial erythema was evaluated as a secondary efficacy outcome measure. Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability. Patients were followed for 28 days posttreatment to assess worsening of erythema (1-grade increase in severity from baseline on composite CEA/SSA in patients with moderate erythema at baseline; rebound effect). The study included 445 patients (mean age: 50.3 years; 78.7{\%} female); most had moderate erythema at baseline (84.0{\%} on CEA; 91.5{\%} on SSA). The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P=0.011, respectively). Median reduction in rosacea facial erythema on day 29 as assessed by digital image analysis also favored oxymetazoline over vehicle (P less than 0.001). Safety results were similar between oxymetazoline and vehicle; discontinuations due to TEAEs were low (2.7{\%} vs 0.5{\%}). Following cessation of treatment, 2 (1.2{\%}) patients in the oxymetazoline group and no patient in the vehicle group had rebound effect compared with their day 1 baseline score. Topical oxymetazoline applied to the face once daily for 29 days was effective, safe, and well tolerated in the treatment of moderate to severe persistent facial erythema of rosacea. J Drugs Dermatol. 2018;17(3):290-298..",
author = "Leslie Baumann and Goldberg, {David J.} and {Stein Gold}, Linda and Tanghetti, {Emil A.} and Edward Lain and Joely Kaufman and Emily Weng and Berk, {David R.} and Gurpreet Ahluwalia",
year = "2018",
month = "3",
day = "1",
language = "English (US)",
volume = "17",
pages = "290--298",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "3",

}

TY - JOUR

T1 - Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea

T2 - Findings from the Second REVEAL Trial

AU - Baumann, Leslie

AU - Goldberg, David J.

AU - Stein Gold, Linda

AU - Tanghetti, Emil A.

AU - Lain, Edward

AU - Kaufman, Joely

AU - Weng, Emily

AU - Berk, David R.

AU - Ahluwalia, Gurpreet

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Rosacea is a chronic dermatologic condition with limited treatment options, particularly for persistent erythema. This pivotal phase 3 study evaluated oxymetazoline, an a1A-adrenoceptor agonist, for the treatment of moderate to severe persistent erythema of rosacea. Eligible patients were randomly assigned 1:1 to receive oxymetazoline cream 1.0% or vehicle applied topically to the face once daily for 29 days. The primary efficacy outcome was ≥2-grade improvement from baseline on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success) at 3, 6, 9, and 12 hours postdose on day 29. Digital image analysis of rosacea facial erythema was evaluated as a secondary efficacy outcome measure. Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability. Patients were followed for 28 days posttreatment to assess worsening of erythema (1-grade increase in severity from baseline on composite CEA/SSA in patients with moderate erythema at baseline; rebound effect). The study included 445 patients (mean age: 50.3 years; 78.7% female); most had moderate erythema at baseline (84.0% on CEA; 91.5% on SSA). The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P=0.011, respectively). Median reduction in rosacea facial erythema on day 29 as assessed by digital image analysis also favored oxymetazoline over vehicle (P less than 0.001). Safety results were similar between oxymetazoline and vehicle; discontinuations due to TEAEs were low (2.7% vs 0.5%). Following cessation of treatment, 2 (1.2%) patients in the oxymetazoline group and no patient in the vehicle group had rebound effect compared with their day 1 baseline score. Topical oxymetazoline applied to the face once daily for 29 days was effective, safe, and well tolerated in the treatment of moderate to severe persistent facial erythema of rosacea. J Drugs Dermatol. 2018;17(3):290-298..

AB - Rosacea is a chronic dermatologic condition with limited treatment options, particularly for persistent erythema. This pivotal phase 3 study evaluated oxymetazoline, an a1A-adrenoceptor agonist, for the treatment of moderate to severe persistent erythema of rosacea. Eligible patients were randomly assigned 1:1 to receive oxymetazoline cream 1.0% or vehicle applied topically to the face once daily for 29 days. The primary efficacy outcome was ≥2-grade improvement from baseline on both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for rosacea facial redness (SSA) (composite success) at 3, 6, 9, and 12 hours postdose on day 29. Digital image analysis of rosacea facial erythema was evaluated as a secondary efficacy outcome measure. Safety assessments included treatment-emergent adverse events (TEAEs) and dermal tolerability. Patients were followed for 28 days posttreatment to assess worsening of erythema (1-grade increase in severity from baseline on composite CEA/SSA in patients with moderate erythema at baseline; rebound effect). The study included 445 patients (mean age: 50.3 years; 78.7% female); most had moderate erythema at baseline (84.0% on CEA; 91.5% on SSA). The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P=0.011, respectively). Median reduction in rosacea facial erythema on day 29 as assessed by digital image analysis also favored oxymetazoline over vehicle (P less than 0.001). Safety results were similar between oxymetazoline and vehicle; discontinuations due to TEAEs were low (2.7% vs 0.5%). Following cessation of treatment, 2 (1.2%) patients in the oxymetazoline group and no patient in the vehicle group had rebound effect compared with their day 1 baseline score. Topical oxymetazoline applied to the face once daily for 29 days was effective, safe, and well tolerated in the treatment of moderate to severe persistent facial erythema of rosacea. J Drugs Dermatol. 2018;17(3):290-298..

UR - http://www.scopus.com/inward/record.url?scp=85048749363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048749363&partnerID=8YFLogxK

M3 - Article

C2 - 29537447

AN - SCOPUS:85048749363

VL - 17

SP - 290

EP - 298

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -